Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Allergan
NCT05878951 · Urinary Incontinence, Overactive Bladder Syndrome, and more
NCT07432659 · Overactive Bladder
NCT06789406 · Urinary Urge Incontinence (UUI), Urinary Frequency (UF), and more
NCT07494864 · Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter, and more
NCT07473310 · Overactive Bladder (OAB), Urge Incontinence
Royal Oak, Michigan
Randwick, New South Wales
Innsbruck
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions